Milestone Pharmaceuticals Inc. (MIST) stock: key figures, P/E, revenue and dividend
Health Care · Canada · ISIN CA59935V1076
Milestone Pharmaceuticals Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -62.14 m USD |
| EBIT | -62.14 m USD |
| Net income | -63.06 m USD |
| Diluted EPS – continuing operations | -0.75 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
More stocks
- Covalon Technologies Ltd. (COV.V)
- JI-Tech Co., Ltd. (417500.KQ)
- Reitmans Canada Ltd (RET.V)
- Maronan Metals Ltd (MMA.AX)
- Lytix Biopharma AS (LYTIX.OL)
- AIR T INC (AIRT)
- Rich Honour International Designs Co Ltd (6754.TW)
- Paramount Gold Nevada Corp. (PZG)
- Panamera Holdings Corp (PHCI)
- JUNIATA VALLEY FINANCIAL CORP (JUVF)
- Questerre Energy Corporation (QEC.TO)
- EURO CREATIONS PUBLIC COMPANY LIMITED (EURO.BK)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.